Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Liabilities and Shareholders Equity (2016 - 2025)

United Therapeutics (UTHR) has disclosed Liabilities and Shareholders Equity for 17 consecutive years, with $7.9 billion as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 7.01% to $7.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.9 billion through Dec 2025, up 11.47% year-over-year, with the annual reading at $7.9 billion for FY2025, 7.01% up from the prior year.
  • Liabilities and Shareholders Equity hit $7.9 billion in Q4 2025 for United Therapeutics, up from $7.4 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $7.9 billion in Q2 2025 to a low of $4.6 billion in Q1 2021.
  • Historically, Liabilities and Shareholders Equity has averaged $6.4 billion across 5 years, with a median of $6.6 billion in 2023.
  • Biggest five-year swings in Liabilities and Shareholders Equity: grew 21.48% in 2023 and later increased 0.63% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $5.2 billion in 2021, then grew by 16.94% to $6.0 billion in 2022, then rose by 18.57% to $7.2 billion in 2023, then rose by 2.75% to $7.4 billion in 2024, then rose by 7.01% to $7.9 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for UTHR at $7.9 billion in Q4 2025, $7.4 billion in Q3 2025, and $7.9 billion in Q2 2025.